Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2012 | editorial | Ausgabe 4/2012

memo - Magazine of European Medical Oncology 4/2012

The individualization of treatment based on molecular markers

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 4/2012
Autor:
MD Prof. Vladimir M. Moiseyenko

Abstract

Recent developments have revealed various decisive discoveries in individualized oncology for many different entities—the individualization of treatment based on molecular markers representing just one of those milestones. The implication of epidermal growth factor receptor (EGFR) mutations for EGFR-tyrosine kinase inhibitor (TKI) treatment, the definition of the HER2 status in breast cancer and the application of the KRAS mutation analysis in colorectal cancer are examples for this development. All these activities have also been the major focus at the Cancer Research Institute in St. Petersburg, where I worked for many years. Within the last years, a growing connection between basic research activities and clinical application can be observed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2012

memo - Magazine of European Medical Oncology 4/2012 Zur Ausgabe